Rock Springs Capital Management LP boosted its stake in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE – Free Report) by 3.6% in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,384,269 shares of the biopharmaceutical company’s stock after purchasing an additional 47,868 shares during […]
Candriam S.C.A. lessened its position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE – Free Report) by 18.4% during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 49,480 shares of the biopharmaceutical company’s stock after selling 11,155 shares during the period. Candriam S.C.A. owned approximately 0.07% of Ultragenyx Pharmaceutical […]
Ultragenyx Pharmaceutical (NASDAQ:RARE – Get Free Report) will issue its quarterly earnings data after the market closes on Thursday, November 2nd. Analysts expect the company to announce earnings of ($2.08) per share for the quarter. Ultragenyx Pharmaceutical has set its FY 2023 guidance at EPS.Individual interested in listening to the company’s earnings conference call can […]
Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) Receives Consensus Rating of Moderate Buy from Analysts etfdailynews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from etfdailynews.com Daily Mail and Mail on Sunday newspapers.
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE – Free Report) – Analysts at Wedbush cut their FY2027 earnings per share (EPS) estimates for shares of Ultragenyx Pharmaceutical in a research note issued on Monday, October 16th. Wedbush analyst L. Chico now expects that the biopharmaceutical company will post earnings of $0.93 per share for the year, down from […]